Literature DB >> 15613930

The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease.

Hiroshi Nagayama1, Makoto Hamamoto, Masayuki Ueda, Chikako Nito, Hiroshi Yamaguchi, Yasuo Katayama.   

Abstract

Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage without losing its effectiveness. The current study sought to determine whether AsA affects LD absorption in elderly PD patients. Sixty-seven elderly PD patients took a tablet orally containing 100 mg LD and 10 mg carbidopa following an overnight fast. Plasma LD concentrations were determined at 6 points up to 3 hours, using high-performance liquid chromatography with electrochemical detection. The area under the curve (AUC), peak drug concentration (Cmax), and time to peak drug concentration (Tmax) were calculated. The pharmacokinetic evaluation was repeatedly performed 1 week later in the same way except for adding 200 mg AsA to the tablet. The changes in AUC, Cmax, and Tmax between the tests were evaluated. Significant changes in these parameters were not observed when analyzed using data from all patients. However, significant increases in AUC and Cmax, and a significant reduction in Tmax by adding AsA were observed in 25 patients with baseline AUC < or =2500 ng.hour/mL. In conclusion, AsA can improve LD absorption in elderly PD patients with poor LD bioavailability. LD therapy in combination with AsA may be one of the strategies for PD treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15613930     DOI: 10.1097/01.wnf.0000150865.21759.bc

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  13 in total

Review 1.  Nrf2/ARE Pathway as a Therapeutic Target for the Treatment of Parkinson Diseases.

Authors:  Artem P Gureev; Vasily N Popov
Journal:  Neurochem Res       Date:  2019-01-07       Impact factor: 3.996

Review 2.  Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review.

Authors:  Priyajit Banerjee; Ishita Saha; Diptendu Sarkar; Arpan Kumar Maiti
Journal:  Neurotox Res       Date:  2022-04-07       Impact factor: 3.911

Review 3.  Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2.

Authors:  Fiona E Harrison; James M May
Journal:  Free Radic Biol Med       Date:  2009-01-06       Impact factor: 7.376

4.  Effect of Oral Coadministration of Ascorbic Acid with Ling Zhi Preparation on Pharmacokinetics of Ganoderic Acid A in Healthy Male Subjects: A Randomized Crossover Study.

Authors:  Patcharanee Tawasri; Chadarat Ampasavate; Somsak Tharatha; Natthakarn Chiranthanut; Supanimit Teekachunhatean
Journal:  Biomed Res Int       Date:  2016-09-25       Impact factor: 3.411

Review 5.  Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?

Authors:  Joanna Kocot; Dorota Luchowska-Kocot; Małgorzata Kiełczykowska; Irena Musik; Jacek Kurzepa
Journal:  Nutrients       Date:  2017-06-27       Impact factor: 5.717

6.  Evaluating Dose- and Time-Dependent Effects of Vitamin C Treatment on a Parkinson's Disease Fly Model.

Authors:  Huynh Man Anh; Dao My Linh; Vuu My Dung; Dang Thi Phuong Thao
Journal:  Parkinsons Dis       Date:  2019-01-02

Review 7.  New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.

Authors:  Marina Lorente-Picón; Ariadna Laguna
Journal:  Biomolecules       Date:  2021-03-15

Review 8.  Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities.

Authors:  Ana Patricia Duarte-Jurado; Yareth Gopar-Cuevas; Odila Saucedo-Cardenas; Maria de Jesus Loera-Arias; Roberto Montes-de-Oca-Luna; Aracely Garcia-Garcia; Humberto Rodriguez-Rocha
Journal:  Antioxidants (Basel)       Date:  2021-03-15

9.  Study on the Regulation Effect of Optogenetic Technology on LFP of the Basal Ganglia Nucleus in Rotenone-Treated Rats.

Authors:  Zongya Zhao; Yanxiang Niu; Peiqi Chen; Yu Zhu; Liangliang Shi; Xuewei Zhao; Chang Wang; Yehong Zhang; Zhixian Gao; Wenshuai Jiang; Wu Ren; Renjun Gu; Yi Yu
Journal:  Neural Plast       Date:  2021-07-28       Impact factor: 3.599

10.  Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review.

Authors:  Jikke T Boelens Keun; Ilse Ac Arnoldussen; Chris Vriend; Ondine van de Rest
Journal:  Adv Nutr       Date:  2021-12-01       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.